EP0738106B1 - Sterilisation par l'acide peracetique - Google Patents
Sterilisation par l'acide peracetique Download PDFInfo
- Publication number
- EP0738106B1 EP0738106B1 EP95907315A EP95907315A EP0738106B1 EP 0738106 B1 EP0738106 B1 EP 0738106B1 EP 95907315 A EP95907315 A EP 95907315A EP 95907315 A EP95907315 A EP 95907315A EP 0738106 B1 EP0738106 B1 EP 0738106B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- peracetic acid
- collagen
- solution
- tissue
- sterilization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 title claims abstract description 154
- 230000001954 sterilising effect Effects 0.000 title claims abstract description 30
- 238000004659 sterilization and disinfection Methods 0.000 title abstract description 27
- 102000008186 Collagen Human genes 0.000 claims abstract description 62
- 108010035532 Collagen Proteins 0.000 claims abstract description 62
- 229920001436 collagen Polymers 0.000 claims abstract description 62
- 230000008961 swelling Effects 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 abstract description 15
- 238000002513 implantation Methods 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 71
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 35
- 239000000463 material Substances 0.000 description 25
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 23
- 239000002953 phosphate buffered saline Substances 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000000968 intestinal effect Effects 0.000 description 13
- 239000001974 tryptic soy broth Substances 0.000 description 8
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004876 tela submucosa Anatomy 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 description 4
- 235000019800 disodium phosphate Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920002274 Nalgene Polymers 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 102000013373 fibrillar collagen Human genes 0.000 description 3
- 108060002894 fibrillar collagen Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- KEAYESYHFKHZAL-OUBTZVSYSA-N sodium-24 Chemical compound [24Na] KEAYESYHFKHZAL-OUBTZVSYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003330 sporicidal effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0215—Disinfecting agents, e.g. antimicrobials for preserving living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group; Thio analogues thereof
Definitions
- This invention is in the field of tissue engineering.
- the invention is directed to the sterilization of collagen and collagenous tissue which is to be used for implantation, repair, or use in a mammalian host.
- the sterilants are low or dilute concentrations of peracetic acid in either neutral or high ionic strength solutions that permit sterilization of the collagenous tissue with a minimal amount of swelling and dissolution so that the collagen retains its structural integrity and bioremodelable properties.
- Tissue engineering is an emerging field combining both methods of the engineering and the principles of life sciences to understand the structural and functional relationships in normal and pathological mammalian tissues.
- the goal of tissue engineering is the development and ultimate application of biological substitutes to restore, maintain or improve tissue functions. Skalak, R. and Fox, C.F., "Tissue Engineering,” Alan R. Liss Inc. N.Y. (1988).
- One major component of these biological substitutes can be collagen or collagenous tissue. While major strides have been made in this field, and are continuing to be made, there is a constant need for improvement of both the biological substitutes and the processes for making and using them. There currently exists a need for a sterilization method that maintains the biological and physical properties of collagen and collagenous tissues used in tissue engineering. The search for sterilants to sterilize collagen and collagenous tissue has resulted in the use of a variety of different methods.
- Ethyl and isopropyl alcohol are not sporicidal.
- Organic mercurials are toxic and have an injurious effect on bone osteoinductive protein.
- Beta-propiolactone is only effective for surface sterilization and, because of its carcinogenicity, it has been removed from the market.
- Ethylene oxide has been used successfully for sterilization of bone, but can dissolve soft tissue.
- Peracetic acid is a known germicidal sterilant.
- aqueous or aqueous-ethanol peracetic acid solutions have been used typically to sterilize surfaces of instruments. Malchesky, P.S., "Peracetic Acid and Its Application to Medical Instrument Sterilization,” Artificial Organs, 17:147-152 (1993). Sterilization of collagenous tissues by peracetic acid using these known techniques, however, is adversely affected by the swelling and dissolution of the collagen caused by the acidity of the solution.
- peracetic acid solutions can prevent or minimize the swelling and dissolution of collagen and collagenous tissue so that the tissue retains its structural integrity and bioremodelable properties.
- These peracetic acid solutions can be successfully used to sterilize biomedical products containing collagen or collagenous tissue that are to be used for implantation, repair, or use in tissue engineering without the attendant problems due to traditional sterilization methods.
- peracetic acid diluted in a neutral or high ionic strength solution is an effective sterilant for collagen and collagenous tissue, preventing or minimizing the swelling and dissolution of the tissue.
- Peracetic acid is a strong oxidizing agent, sold commercially in approximately 35% concentration.
- a low concentration or dilute peracetic acid solution will typically contain less than 5% peracetic acid, preferably less than 1%, typically in a range between 0.1% to 0.5%, and more preferred less than 0.5%, typically in a range between 0.02% to 0.1%.
- the strength of the peracetic acid in the dilute peracetic acid solution is not critical, but it is preferred to use a lower concentration of peracetic acid so that tissue is not damaged.
- the degree of the microbiological load, or bioburden, of the collagen or collagenous tissue may indicate that a higher concentration of peracetic add is needed, and the solution can be adjusted accordingly.
- the aqueous solution used to dilute the peracetic acid can be any solution that is compatible with collagen, for example, buffered or unbuffered water or saline, or solutions of sodium chloride.
- the preferred solution is either a buffered solution for ease in adjusting the pH of the dilute peracetic acid solution to neutral pH or a solution of 1M sodium chloride.
- Storage solutions for the collagenous bone grafts can also be used to dilute the peracetic acid; these are typically phosphate buffered saline solutions.
- the pH of the low concentration, or dilute, peracetic acid solution is adjusted to neutralize the pH of the solution.
- the pH of the dilute peracetic acid solution is first measured with a pH meter or with pH paper.
- the solution is slowly neutralized by adding a base to the solution. Adjusting the pH is accomplished more easily by first dissolving the base in an aqueous solution. The pH is then adjusted until the pH of the solution is neutral.
- neutral pH is meant to cover a pH range from 6.0 to 8.0 pH. The preferred pH range is from 7.0 to 7.5 pH.
- the sterilizing solution is made from peracetic acid diluted in an aqueous solution with a high ionic strength, typically a high salt concentration.
- a "high salt concentration” can be any concentration of salt that is effective to prevent collagen from swelling at low pH.
- the aqueous high salt concentration solution can be any concentration from 500mM to 3M, preferably from about 1M to about 2M.
- the salt that can be used in this invention can be sodium chloride, potassium chloride, calcium chloride, and the like. This dilute peracetic acid sterilizing solution with high salt concentration does not need to be pH adjusted.
- the actual sterilization step is accomplished by soaking or washing the collagen or collagenous tissue with the dilute peracetic add sterilization solution for a time and under conditions sufficient to achieve sterilization.
- the time for the sterilization will depend in part upon the size and type of the collagen or collagenous tissue to be sterilized, the manner of applying the sterilization solution, and the amount of bioburden.
- the sterilization time will typically be from 5 minutes to 30 hours.
- the peracetic acid sterilization solution can be rinsed from the collagen or collagenous tissue, typically with the sterile water, saline, buffer, or storage media.
- the tissue graft can be placed directly into the sterile storage media without rinsing.
- Collagen and collagenous tissue that can be sterilized according to this invention can include autogenous, allogenous, and xenogenous materials.
- biomedical materials that can be sterilized are, but are not limited to, veins, tendons, dermis, heart valves, stomach smooth muscle tissue, and small intestine submucosa.
- Collagenous tissue also includes collagen matrix structures and constructs. Since collagen is the basic building block that provides the structural framework for dermis, arteries, veins, tubular structures and most other human organs, the ability of the peracetic acid sterilant of this invention to sterilize collagenous biomaterials without damage is important.
- DFC Dense Fibrillar Collagen
- U.S. 5 378 469 is a homogenous natural collagen that can be remodeled into living tissue and organ equivalents by the host.
- DFC can be produced in many forms, allowing for the development of many different collagen-based products. These biomedical products have broad applications in organ and tissue replacement therapy because they are designed to be similar to their counter parts in the human body and encourage natural healing.
- Phosphate buffered saline (PBS) solution was made from 0.144 grams potassium phosphate monobasic; 3.00 grams sodium phosphate dibasic (7H 2 O); 9.00 grams sodium chloride; and 1 liter purified water.
- the following example describes the preparation of the sterilant: dilute, high salt concentration, peracetic acid solution.
- Sections of intestinal collagen material (approximately 3 inches long) were prepared as described in Example 3 and blotted dry, weighed and placed in 50 mls of one of the above dilute peracetic acid solutions (the experiment was performed in triplicate). After 19 hours incubation at room temperature, the samples were transferred to fresh solution and left for a further 28 hours. Samples were then removed, blotted briefly to remove surface liquid and re-weighed.
- Sections of dry DFC sheet (stored dry for more than 6 months) were weighed and placed in 50 mls of one of the above solutions (the experiment was performed in duplicate). After 19 hours incubation at room temperature, the samples were removed, blotted briefly to remove surface liquid and re-weighed.
- Dense Fibrillar Collagen (DFC) thread production is described in U.S. 5,378,469.
- a 140 ml syringe containing a 5.0 mg/ml collagen solution in 8.8 mM acetic acid was loaded in a syringe pump (Harvard Apparatus, South Natick, MA) set to infuse at 2.50 ml/min.
- Silicone tubing (1/8-inch ID) connected the syringe to an 18-gauge blunt stainless steel needle immersed in one end of an 18-foot long, 2-inch diameter PVC trough containing 5L of 20% polyethylene glycol (PEG), MW 8000 (Spectrum Chemicals, New Brunswick, NJ), in 94 mM sodium phosphate dibasic and 24 mM sodium phosphate monobasic at pH 7.55.
- PEG polyethylene glycol
- MW 8000 Spectrum Chemicals, New Brunswick, NJ
- a peristaltic pump was used to recirculate the PEG solution such that the fluid velocity at the needle tip was about 4 cm/sec.
- the circulating PEG solution drew the collagen away from the needle orifice, thus forming a continuous filament.
- the coagulation trough was configured such that the residence time of the thread in the bath was approximately 4 minutes. As the thread accumulated, it was manually transferred to a 6 foot long trough filled with 5.5 mM sodium phosphate dibasic, 0.5 mM potassium phosphate monobasic and 75 mM NaCl at pH 7.10, and remained there for 5 to 10 minutes.
- the thread was then partially dehydrated by passing it through a 2 foot long trough containing 70% isopropanol, and dried under tension by drawing it over a series of Teflon pulleys inside a cabinet heated with air blowers. To prevent the collagen from being heat denatured, the thread was kept in motion, and was always at least 15 cm from the blowers. Finally, the thread was spooled onto a level winding device. The tension on the thread during the drying was such that its length doubled before it emerged dry from the cabinet. The total residence time in the cabinet was approximately 3 minutes.
- the filament was threaded through the entire system, it could be produced continuously; the operator needed only to keep the coagulation and rinsing reservoirs filled with enough slack to permit reeling.
- Shrinkage temperature a measure of the stability of the collagen triple helix, was measured by immersing a 5 to 7 cm loop of thread loaded with 2.5 g in 1.0 mM potassium phosphate monobasic, 11 mM sodium phosphate dibasic, and 150 mM NaCl at pH 7.30, and heating at 1°C per minute until shrinkage occurred. The temperature at which the sample shrank by at least 10% was recorded as the shrinkage temperature.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
Claims (4)
- Procédé de stérilisation de collagène ou de tissu de collagène comprenant la mise en contact dudit collagène ou tissu de collagène avec une solution d'acide peracétique qui stérilise ledit collagène ou tissu de collagène sans aucun ou avec une quantité minimale de gonflement et de dissolution, dans lequel ladite solution a une concentration en acide peracétique dans l'intervalle de 0,02% à 1,0%, caractérisé en ce que :i. la solution a un pH neutralisé de 6,0 à 8,0; et/ouii. la solution a une concentration en sel de 1 M à 2 M.
- Procédé suivant la revendication 1, dans lequel la solution a une concentration de 0,1% d'acide peracétique.
- Utilisation d'une solution d'acide peracétique ayant une concentration en acide peracétique dans l'intervalle de 0,02% à 1,0% dans la préparation d'un agent de stérilisation de collagène ou de tissu de collagène caractérisée en ce que :i. la solution a un pH neutralisé de 6,0 à 8,0; et/ouii. la solution a une concentration en sel de 1 M à 2 M.
- Utilisation suivant la revendication 3, dans laquelle la solution a une concentration de 0,1% d'acide peracétique.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/177,618 US5460962A (en) | 1994-01-04 | 1994-01-04 | Peracetic acid sterilization of collagen or collagenous tissue |
PCT/US1995/000126 WO1995018529A1 (fr) | 1994-01-04 | 1995-01-04 | Sterilisation par l'acide peracetique |
US177618 | 2002-06-20 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0738106A1 EP0738106A1 (fr) | 1996-10-23 |
EP0738106A4 EP0738106A4 (fr) | 1997-05-28 |
EP0738106B1 true EP0738106B1 (fr) | 2001-08-16 |
Family
ID=22649287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95907315A Expired - Lifetime EP0738106B1 (fr) | 1994-01-04 | 1995-01-04 | Sterilisation par l'acide peracetique |
Country Status (11)
Country | Link |
---|---|
US (1) | US5460962A (fr) |
EP (1) | EP0738106B1 (fr) |
JP (2) | JP3708961B2 (fr) |
AT (1) | ATE204122T1 (fr) |
CA (1) | CA2179017C (fr) |
DE (1) | DE69522203T2 (fr) |
DK (1) | DK0738106T3 (fr) |
ES (1) | ES2161281T3 (fr) |
MX (1) | MX9602545A (fr) |
PT (1) | PT738106E (fr) |
WO (1) | WO1995018529A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10220114B2 (en) | 2008-04-29 | 2019-03-05 | Proxy Biomedical Limited | Tissue repair implant |
US11026980B1 (en) | 2018-02-26 | 2021-06-08 | Triad Life Sciences, Inc. | Flowable birth tissue composition and related methods |
US11602548B1 (en) | 2018-02-26 | 2023-03-14 | Convatec, Inc | Fibrous birth tissue composition and method of use |
Families Citing this family (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040067157A1 (en) * | 1993-07-22 | 2004-04-08 | Clearant, Inc. | Methods for sterilizing biological materials |
US5362442A (en) | 1993-07-22 | 1994-11-08 | 2920913 Canada Inc. | Method for sterilizing products with gamma radiation |
US5713950A (en) * | 1993-11-01 | 1998-02-03 | Cox; James L. | Method of replacing heart valves using flexible tubes |
US6334872B1 (en) * | 1994-02-18 | 2002-01-01 | Organogenesis Inc. | Method for treating diseased or damaged organs |
US5733337A (en) * | 1995-04-07 | 1998-03-31 | Organogenesis, Inc. | Tissue repair fabric |
US20020095218A1 (en) | 1996-03-12 | 2002-07-18 | Carr Robert M. | Tissue repair fabric |
US20040002772A1 (en) * | 1995-04-28 | 2004-01-01 | Organogenesis, Inc. | Tissue equivalents with perforations for improved integration to host tissues and methods for producing perforated tissue equivalents |
US5677284A (en) * | 1995-06-06 | 1997-10-14 | Regen Biologics, Inc. | Charged collagen particle-based delivery matrix |
US5788941A (en) * | 1996-01-31 | 1998-08-04 | Steris Corporation | Method of sterilization of bone tussue |
US8716227B2 (en) * | 1996-08-23 | 2014-05-06 | Cook Biotech Incorporated | Graft prosthesis, materials and methods |
DE69725592T2 (de) * | 1996-08-23 | 2004-08-05 | Cook Biotech, Inc., West Lafayette | Verfahren zur gewinnung einer gereignigten matrix auf kollagenbasis aus submukosa gewebe |
US6666892B2 (en) * | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
CA2267310C (fr) * | 1996-12-10 | 2012-09-18 | Purdue Research Foundation | Greffon issu de la sous-muqueuse gastrique |
EP1300154B1 (fr) * | 1996-12-10 | 2005-09-14 | Purdue Research Foundation | Greffon issu de la sous-muqueuse gastrique |
PL184497B1 (pl) * | 1996-12-10 | 2002-11-29 | Purdue Research Foundation | Cylindryczna proteza z tkanki podśluzówkowej i sposób wytwarzania cylindrycznej protezy z tkanki podśluzówkowej |
AU774997C (en) * | 1997-05-08 | 2005-06-30 | Organogenesis Inc. | Chemical cleaning of biological material |
US5993844A (en) * | 1997-05-08 | 1999-11-30 | Organogenesis, Inc. | Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix |
US20010031254A1 (en) * | 1998-11-13 | 2001-10-18 | Bianchi John R. | Assembled implant |
US6482584B1 (en) | 1998-11-13 | 2002-11-19 | Regeneration Technologies, Inc. | Cyclic implant perfusion cleaning and passivation process |
US7070607B2 (en) * | 1998-01-27 | 2006-07-04 | The Regents Of The University Of California | Bioabsorbable polymeric implants and a method of using the same to create occlusions |
AUPP276098A0 (en) * | 1998-04-01 | 1998-04-30 | Nokuta Pty Ltd | A method for treating gelatine |
EP1082057B1 (fr) * | 1998-06-05 | 2009-02-25 | Organogenesis Inc. | Protheses implantables tubulaires obtenues par genie genetique |
AU753773B2 (en) * | 1998-06-05 | 2002-10-31 | Organogenesis Inc. | Bioengineered vascular graft prostheses |
AU754838B2 (en) * | 1998-06-05 | 2002-11-28 | Organogenesis Inc. | Bioengineered flat sheet graft prostheses |
AU763724B2 (en) | 1998-06-05 | 2003-07-31 | Duke University School Of Medicine | Bioengineered vascular graft support prostheses |
US6214054B1 (en) | 1998-09-21 | 2001-04-10 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
WO2000030690A1 (fr) * | 1998-11-23 | 2000-06-02 | Ecolab Inc. | Composition de sterilisation non-corrosive |
US8882850B2 (en) | 1998-12-01 | 2014-11-11 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
DE69939370D1 (de) * | 1998-12-01 | 2008-10-02 | Cook Biotech Inc | Medizinischer artikel aus unterschiedlich hergestelltem kollagen-biomaterial |
DE69939685D1 (de) * | 1998-12-01 | 2008-11-20 | Univ Washington | Vorrichtung zur intravaskulären embolisierung |
US6592623B1 (en) | 1999-08-31 | 2003-07-15 | Virginia Commonwealth University Intellectual Property Foundation | Engineered muscle |
US7615373B2 (en) * | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
US20020081732A1 (en) * | 2000-10-18 | 2002-06-27 | Bowlin Gary L. | Electroprocessing in drug delivery and cell encapsulation |
US20040116032A1 (en) * | 1999-02-25 | 2004-06-17 | Bowlin Gary L. | Electroprocessed collagen |
ATE424162T1 (de) * | 1999-08-06 | 2009-03-15 | Cook Biotech Inc | Rohrförmige transplantatkonstruktion |
US6592794B1 (en) * | 1999-09-28 | 2003-07-15 | Organogenesis Inc. | Process of making bioengineered collagen fibrils |
US6866686B2 (en) * | 2000-01-28 | 2005-03-15 | Cryolife, Inc. | Tissue graft |
ATE346563T1 (de) | 2000-03-10 | 2006-12-15 | Paracor Medical Inc | Expandierbarer herzbeutel zur behandlung von kongestiven herzversagens |
US20040086420A1 (en) * | 2000-03-23 | 2004-05-06 | Macphee Martin J. | Methods for sterilizing serum or plasma |
US6638312B2 (en) | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
US8366787B2 (en) | 2000-08-04 | 2013-02-05 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
AU2001287023A1 (en) | 2000-09-01 | 2002-03-13 | Virginia Commonwealth University Intellectual Property Foundation | Plasma-derived-fibrin-based matrices and tissue |
JP2004508305A (ja) * | 2000-09-01 | 2004-03-18 | ヴァージニア コモンウェルス ユニバーシティ インテレクチュアル プロパティー ファンデーション | 電気処理されたフィブリンをベースとするマトリックスおよび組織 |
EP1320390A2 (fr) * | 2000-09-18 | 2003-06-25 | Organogenesis Inc. | Procedes de traitement de patients a l'aide de protheses greffees a feuilles planes cultivees par genie genetique |
DE10047300A1 (de) * | 2000-09-25 | 2002-04-18 | Gustav Steinhoff | Bioartifizielles Verbundmaterial und Verfahren zu seiner Herstellung |
US6682695B2 (en) * | 2001-03-23 | 2004-01-27 | Clearant, Inc. | Methods for sterilizing biological materials by multiple rates |
US6696060B2 (en) | 2001-06-14 | 2004-02-24 | Clearant, Inc. | Methods for sterilizing preparations of monoclonal immunoglobulins |
EP1416888A4 (fr) | 2001-07-16 | 2007-04-25 | Depuy Products Inc | Dispositif et procede de regeneration du menisque |
WO2003007805A2 (fr) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Appareil de reparation de cartilages et procede associe |
US7914808B2 (en) | 2001-07-16 | 2011-03-29 | Depuy Products, Inc. | Hybrid biologic/synthetic porous extracellular matrix scaffolds |
WO2003007787A2 (fr) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Dispositif et procede de reparation et de regeneration du cartilage |
US20030032961A1 (en) | 2001-07-16 | 2003-02-13 | Pelo Mark Joseph | Devices from naturally occurring biologically derived materials |
US7201917B2 (en) | 2001-07-16 | 2007-04-10 | Depuy Products, Inc. | Porous delivery scaffold and method |
JP4302515B2 (ja) | 2001-07-16 | 2009-07-29 | デピュイ・プロダクツ・インコーポレイテッド | 単体型外科装置および方法 |
US7819918B2 (en) | 2001-07-16 | 2010-10-26 | Depuy Products, Inc. | Implantable tissue repair device |
US8025896B2 (en) | 2001-07-16 | 2011-09-27 | Depuy Products, Inc. | Porous extracellular matrix scaffold and method |
US6946098B2 (en) | 2001-08-10 | 2005-09-20 | Clearant, Inc. | Methods for sterilizing biological materials |
US20030031584A1 (en) * | 2001-08-10 | 2003-02-13 | Wilson Burgess | Methods for sterilizing biological materials using dipeptide stabilizers |
RU2264294C2 (ru) | 2001-08-24 | 2005-11-20 | Мэттью Р. КУУК | Держатель контейнера для напитков |
US6749851B2 (en) | 2001-08-31 | 2004-06-15 | Clearant, Inc. | Methods for sterilizing preparations of digestive enzymes |
US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
CA2458023A1 (fr) | 2001-09-10 | 2003-03-20 | Paracor Medical, Inc. | Dispositif de traitement de l'insuffisance cardiaque |
US6783968B2 (en) | 2001-09-24 | 2004-08-31 | Clearant, Inc. | Methods for sterilizing preparations of glycosidases |
US20030185702A1 (en) * | 2002-02-01 | 2003-10-02 | Wilson Burgess | Methods for sterilizing tissue |
US20030095890A1 (en) * | 2001-09-24 | 2003-05-22 | Shirley Miekka | Methods for sterilizing biological materials containing non-aqueous solvents |
US20110091353A1 (en) * | 2001-09-24 | 2011-04-21 | Wilson Burgess | Methods for Sterilizing Tissue |
CA2460307A1 (fr) | 2001-10-31 | 2003-05-08 | Paracor Medical, Inc. | Dispositif de traitement de l'insuffisance cardiaque |
US20030124023A1 (en) * | 2001-12-21 | 2003-07-03 | Wilson Burgess | Method of sterilizing heart valves |
US6878168B2 (en) | 2002-01-03 | 2005-04-12 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
US7022063B2 (en) | 2002-01-07 | 2006-04-04 | Paracor Medical, Inc. | Cardiac harness |
US20030180181A1 (en) * | 2002-02-01 | 2003-09-25 | Teri Greib | Methods for sterilizing tissue |
CA2486919C (fr) | 2002-06-03 | 2011-03-15 | Nmt Medical, Inc. | Dispositif a armature de tissu biologique pour l'obturation de defauts intracardiaques |
US20040013562A1 (en) * | 2002-07-18 | 2004-01-22 | Wilson Burgess | Methods for sterilizing milk. |
US6908591B2 (en) * | 2002-07-18 | 2005-06-21 | Clearant, Inc. | Methods for sterilizing biological materials by irradiation over a temperature gradient |
EP1534173A2 (fr) | 2002-09-05 | 2005-06-01 | Paracor Medical, Inc. | Harnais cardiaque |
US7189203B2 (en) | 2002-11-15 | 2007-03-13 | Paracor Medical, Inc. | Cardiac harness delivery device and method |
US7229405B2 (en) | 2002-11-15 | 2007-06-12 | Paracor Medical, Inc. | Cardiac harness delivery device and method of use |
US7736299B2 (en) | 2002-11-15 | 2010-06-15 | Paracor Medical, Inc. | Introducer for a cardiac harness delivery |
JP2007528749A (ja) | 2003-07-10 | 2007-10-18 | パラコー メディカル インコーポレイテッド | 自己固定心臓ハーネス |
US7155295B2 (en) | 2003-11-07 | 2006-12-26 | Paracor Medical, Inc. | Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing |
US7158839B2 (en) | 2003-11-07 | 2007-01-02 | Paracor Medical, Inc. | Cardiac harness for treating heart disease |
US7282024B2 (en) | 2004-01-12 | 2007-10-16 | Paracor Medical, Inc. | Cardiac harness having interconnected strands |
US7569233B2 (en) | 2004-05-04 | 2009-08-04 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
US8257715B1 (en) | 2004-08-26 | 2012-09-04 | University Of Notre Dame | Tissue vaccines and uses thereof |
US8114841B2 (en) * | 2004-10-14 | 2012-02-14 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
US7513866B2 (en) | 2004-10-29 | 2009-04-07 | Depuy Products, Inc. | Intestine processing device and associated method |
US7354627B2 (en) | 2004-12-22 | 2008-04-08 | Depuy Products, Inc. | Method for organizing the assembly of collagen fibers and compositions formed therefrom |
US20060206139A1 (en) * | 2005-01-19 | 2006-09-14 | Tekulve Kurt J | Vascular occlusion device |
US20100112543A1 (en) * | 2005-03-16 | 2010-05-06 | Manh-Dan Ngo | Processing soft tissue, methods and compositions related thereto |
CA2602100A1 (fr) * | 2005-03-16 | 2006-09-28 | Musculoskeletal Transplant Foundation | Traitement de tissu mou |
WO2006124946A2 (fr) * | 2005-05-16 | 2006-11-23 | Purdue Research Foundation | Matrices extracellulaires manipulees |
MX2007014480A (es) * | 2005-05-19 | 2008-04-22 | Albiorex Llc | Esterilizacion terminal de productos de colageno inyectables. |
US7595062B2 (en) | 2005-07-28 | 2009-09-29 | Depuy Products, Inc. | Joint resurfacing orthopaedic implant and associated method |
US7587247B2 (en) | 2005-08-01 | 2009-09-08 | Paracor Medical, Inc. | Cardiac harness having an optimal impedance range |
US8778362B2 (en) | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof |
US8802113B2 (en) * | 2005-10-27 | 2014-08-12 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
US8778360B2 (en) * | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
US9308252B2 (en) * | 2005-10-27 | 2016-04-12 | Cook Biotech, Inc. | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
US7658706B2 (en) * | 2005-12-05 | 2010-02-09 | Rti Biologics, Inc. | Vascular graft sterilization and decellularization |
CA2641860C (fr) | 2006-02-09 | 2015-07-14 | Biomimetic Therapeutics, Inc. | Compositions et methodes pour le traitement d'os |
JP4045289B2 (ja) * | 2006-04-12 | 2008-02-13 | 株式会社エーシーバイオテクノロジーズ | コラーゲン類生産方法及びコラーゲン類 |
US20070269476A1 (en) | 2006-05-16 | 2007-11-22 | Voytik-Harbin Sherry L | Engineered extracellular matrices control stem cell behavior |
ES2664229T3 (es) | 2006-06-30 | 2018-04-18 | Biomimetic Therapeutics, Llc | Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
ATE529070T1 (de) | 2006-07-31 | 2011-11-15 | Organogenesis Inc | Mastopexie- und brustrekonstruktionsprothesen |
AU2007297611B2 (en) * | 2006-09-21 | 2013-02-07 | Purdue Research Foundation | Collagen preparation and method of isolation |
TW200817055A (en) * | 2006-10-04 | 2008-04-16 | Univ Nat Cheng Kung | Disinfection method for biomaterial |
US10232064B2 (en) | 2006-10-04 | 2019-03-19 | National Cheng Kung University | Method for sterilizing biological materials |
CN103933612B (zh) | 2006-10-27 | 2016-06-22 | 爱德华兹生命科学公司 | 用于外科植入的生物组织 |
EP3181157B1 (fr) | 2006-11-03 | 2019-08-14 | BioMimetic Therapeutics, LLC | Compositions et procédés de procédures arthrodétiques |
US7871440B2 (en) | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
US8343536B2 (en) | 2007-01-25 | 2013-01-01 | Cook Biotech Incorporated | Biofilm-inhibiting medical products |
US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
US8192351B2 (en) | 2007-08-13 | 2012-06-05 | Paracor Medical, Inc. | Medical device delivery system having integrated introducer |
US20090082816A1 (en) | 2007-09-20 | 2009-03-26 | Graham Matthew R | Remodelable orthopaedic spacer and method of using the same |
WO2009076391A2 (fr) | 2007-12-10 | 2009-06-18 | Cook Biotech Incorporated | Matériaux médicaux comprenant des matériaux de matrice extracellulaire modifiés |
US8679176B2 (en) | 2007-12-18 | 2014-03-25 | Cormatrix Cardiovascular, Inc | Prosthetic tissue valve |
US8257434B2 (en) | 2007-12-18 | 2012-09-04 | Cormatrix Cardiovascular, Inc. | Prosthetic tissue valve |
US8357387B2 (en) | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
US8735054B1 (en) | 2008-01-04 | 2014-05-27 | Lifecell Corporation | Acellular tissue matrix preservation solution |
CN105854074B (zh) | 2008-02-07 | 2019-10-15 | 生物模拟治疗有限责任公司 | 用于牵引成骨术的组合物和方法 |
US9283266B2 (en) * | 2008-02-28 | 2016-03-15 | University Of Notre Dame | Metastasis inhibition preparations and methods |
AU2009291828C1 (en) | 2008-09-09 | 2016-03-17 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
CN102316890A (zh) * | 2008-12-19 | 2012-01-11 | 生物模拟治疗公司 | 具有降低的蛋白酶活性的骨移植物以及选择和使用的方法 |
US9150318B1 (en) | 2009-01-02 | 2015-10-06 | Lifecell Corporation | Method for sterilizing an acellular tissue matrix |
SG178070A1 (en) | 2009-08-18 | 2012-03-29 | Lifecell Corp | Method for processing tissues |
WO2011047127A1 (fr) | 2009-10-15 | 2011-04-21 | Minntech Corporation | Système de désinfection de pièce par brumisation |
JP2013512080A (ja) | 2009-12-03 | 2013-04-11 | ミンテック コーポレーション | 医療装置を噴霧によって浄化する容器及びシステム |
US8846059B2 (en) | 2009-12-08 | 2014-09-30 | University Of Notre Dame | Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer |
US20110150934A1 (en) * | 2009-12-18 | 2011-06-23 | University Of Notre Dame | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer |
CN107802890A (zh) | 2010-01-14 | 2018-03-16 | 奥加诺吉尼西斯公司 | 生物工程化组织构建物及其制备和使用方法 |
US8492335B2 (en) | 2010-02-22 | 2013-07-23 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
EP3545980A1 (fr) | 2010-02-26 | 2019-10-02 | DeCell Technologies Inc. | Procédés de décellularisation de tissu |
EP2656863B1 (fr) | 2010-03-23 | 2019-09-18 | Edwards Lifesciences Corporation | Procédés de conditionnement de tissus bioprothétiques en feuille |
EP2549947B1 (fr) | 2010-03-24 | 2017-12-13 | Covidien LP | Implant chirurgical tridimensionnel composite |
US8906601B2 (en) | 2010-06-17 | 2014-12-09 | Edwardss Lifesciences Corporation | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
US8377143B2 (en) | 2010-07-06 | 2013-02-19 | Cryolife, Inc. | Tissue implants for implantation and methods for preparing the same |
ES2788749T3 (es) | 2010-08-26 | 2020-10-22 | Lifecell Corp | Métodos pasivos para mallas biológicas antimicrobianas |
US9351829B2 (en) | 2010-11-17 | 2016-05-31 | Edwards Lifesciences Corporation | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
KR101269618B1 (ko) * | 2011-04-12 | 2013-06-05 | 한스바이오메드 주식회사 | 포유류의 연골조직에서 유래한 생체이식재 |
EP2696908B1 (fr) | 2011-04-14 | 2015-03-11 | Lifecell Corporation | Matériaux régénératifs |
US9017607B2 (en) | 2011-05-27 | 2015-04-28 | Medivators Inc. | Decontamination system including environmental control using a decontaminating substance |
US8845719B2 (en) * | 2011-05-27 | 2014-09-30 | Cormatrix Cardiovascular, Inc | Extracellular matrix material conduits and methods of making and using same |
EP2776080A1 (fr) | 2011-11-10 | 2014-09-17 | Lifecell Corporation | Dispositif pour le traitement d'un tendon et d'un ligament |
KR101330646B1 (ko) | 2012-01-30 | 2013-11-18 | 대한민국(농촌진흥청장) | 동결보존 이종 피부의 제조 방법 및 그로부터 제조된 동결보존 이종 피부 |
ES2716993T3 (es) | 2012-03-08 | 2019-06-18 | Lifecell Corp | Matrices de colágeno y tejido activadas por enzimas |
US10238771B2 (en) | 2012-11-08 | 2019-03-26 | Edwards Lifesciences Corporation | Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system |
US9615922B2 (en) | 2013-09-30 | 2017-04-11 | Edwards Lifesciences Corporation | Method and apparatus for preparing a contoured biological tissue |
US10959839B2 (en) | 2013-10-08 | 2021-03-30 | Edwards Lifesciences Corporation | Method for directing cellular migration patterns on a biological tissue |
US9878071B2 (en) | 2013-10-16 | 2018-01-30 | Purdue Research Foundation | Collagen compositions and methods of use |
AU2014341866B2 (en) | 2013-11-04 | 2018-07-05 | Lifecell Corporation | Methods of removing alpha-galactose |
US9562834B2 (en) | 2014-08-21 | 2017-02-07 | John J. Nelson | Aqueous compositions and methods of using the same for histopathological evaluation of tissue samples |
US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
WO2016172365A1 (fr) | 2015-04-21 | 2016-10-27 | Purdue Research Foundation Office Of Technology Commercialization | Composites de cellule-collagène-silice et procédés de fabrication et d'utilisation correspondants |
AU2016366404A1 (en) | 2015-12-11 | 2018-06-14 | Lifecell Corporation | Methods and systems for stiffening of tissue for improved processing |
US11739291B2 (en) | 2017-04-25 | 2023-08-29 | Purdue Research Foundation | 3-dimensional (3D) tissue-engineered muscle for tissue restoration |
US10722613B2 (en) | 2017-06-29 | 2020-07-28 | St. Jude Medical, Cardiology Division, Inc. | Method of preparing calcification-resistant bioprosthetic tissue |
US11517428B2 (en) | 2018-11-01 | 2022-12-06 | Edwards Lifesciences Corporation | Transcatheter pulmonic regenerative valve |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD93525A (fr) * | ||||
DD217143B1 (de) * | 1983-04-05 | 1986-12-10 | Univ Berlin Humboldt | Verfahren zur herstellung von transplantaten aus skleroproteinen |
US5116575A (en) * | 1986-02-06 | 1992-05-26 | Steris Corporation | Powdered anti-microbial composition |
DD246701A1 (de) * | 1986-03-18 | 1987-06-17 | Univ Berlin Humboldt | Verfahren zur herstellung von xenogenem transplantat |
DE3702983A1 (de) * | 1986-06-09 | 1987-12-10 | Henkel Kgaa | Desinfektionsmittel und ihre verwendung zur haut- und schleimhautdesinfektion |
US5298222A (en) * | 1989-08-09 | 1994-03-29 | Osteotech, Inc. | Process for disinfecting musculoskeletal tissue and tissues prepared thereby |
US5120656A (en) * | 1989-08-18 | 1992-06-09 | Osteotech, Inc. | Process for debriding bone |
-
1994
- 1994-01-04 US US08/177,618 patent/US5460962A/en not_active Expired - Lifetime
-
1995
- 1995-01-04 CA CA002179017A patent/CA2179017C/fr not_active Expired - Lifetime
- 1995-01-04 MX MX9602545A patent/MX9602545A/es unknown
- 1995-01-04 JP JP51859995A patent/JP3708961B2/ja not_active Expired - Fee Related
- 1995-01-04 ES ES95907315T patent/ES2161281T3/es not_active Expired - Lifetime
- 1995-01-04 EP EP95907315A patent/EP0738106B1/fr not_active Expired - Lifetime
- 1995-01-04 PT PT95907315T patent/PT738106E/pt unknown
- 1995-01-04 AT AT95907315T patent/ATE204122T1/de not_active IP Right Cessation
- 1995-01-04 DK DK95907315T patent/DK0738106T3/da active
- 1995-01-04 DE DE69522203T patent/DE69522203T2/de not_active Expired - Lifetime
- 1995-01-04 WO PCT/US1995/000126 patent/WO1995018529A1/fr active IP Right Grant
-
2005
- 2005-05-16 JP JP2005143247A patent/JP3990408B2/ja not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10220114B2 (en) | 2008-04-29 | 2019-03-05 | Proxy Biomedical Limited | Tissue repair implant |
US11026980B1 (en) | 2018-02-26 | 2021-06-08 | Triad Life Sciences, Inc. | Flowable birth tissue composition and related methods |
US11602548B1 (en) | 2018-02-26 | 2023-03-14 | Convatec, Inc | Fibrous birth tissue composition and method of use |
Also Published As
Publication number | Publication date |
---|---|
MX9602545A (es) | 1997-05-31 |
CA2179017A1 (fr) | 1995-07-13 |
JPH09508103A (ja) | 1997-08-19 |
EP0738106A4 (fr) | 1997-05-28 |
EP0738106A1 (fr) | 1996-10-23 |
DE69522203T2 (de) | 2002-05-23 |
US5460962A (en) | 1995-10-24 |
WO1995018529A1 (fr) | 1995-07-13 |
CA2179017C (fr) | 2005-05-03 |
ATE204122T1 (de) | 2001-09-15 |
JP2005320336A (ja) | 2005-11-17 |
PT738106E (pt) | 2001-12-28 |
JP3990408B2 (ja) | 2007-10-10 |
JP3708961B2 (ja) | 2005-10-19 |
DE69522203D1 (de) | 2001-09-20 |
ES2161281T3 (es) | 2001-12-01 |
DK0738106T3 (da) | 2001-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0738106B1 (fr) | Sterilisation par l'acide peracetique | |
Tao et al. | Sterilization and disinfection methods for decellularized matrix materials: Review, consideration and proposal | |
US9205172B2 (en) | Implantable biomaterial and a method of producing same | |
US6561970B1 (en) | Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods | |
US6969523B1 (en) | Collagen/glycosaminoglycan matrix stable to sterilizing by electron beam radiation | |
US4361552A (en) | Wound dressing | |
US10758642B2 (en) | Sterilization process | |
WO2018167536A1 (fr) | Matériau implantable et procédé de conservation | |
BR112020023977A2 (pt) | método para preparar tecido biológico para implante cirúrgico | |
US6379615B1 (en) | Methods of sterilizing articles | |
IL266439A (en) | A transplantable guide for tissue regeneration | |
Moore et al. | Nonaldehyde sterilization of biologic tissue for use in implantable medical devices | |
Neethling et al. | Glutaraldehyde‐fixed kangaroo aortic wall tissue: Histology, crosslink stability and calcification potential | |
US20080085211A1 (en) | Method for Sterilizing Biological Materials | |
US20240173443A1 (en) | Sterilizing biological tissue with supercritical carbon dioxide | |
US10232064B2 (en) | Method for sterilizing biological materials | |
CN117815452A (zh) | 人工血管载药方法及人工血管 | |
Snyder et al. | Michael N. Helmus, Ph. D.; Edward A. Botan, Ph. D.; James M. Malone, MD; Katherine M. Botzko, 4 MS; Richard L. Reinert, BS; Rosemary Bevans-Lynch, BS; Klaus Brendel, Ph. D.; Raymond C. Duhamel, Ph. D.; and |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960715 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19970411 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19990617 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
ITF | It: translation for a ep patent filed |
Owner name: BARZANO' E ZANARDO ROMA S.P.A. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
REF | Corresponds to: |
Ref document number: 204122 Country of ref document: AT Date of ref document: 20010915 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KIRKER & CIE SA Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69522203 Country of ref document: DE Date of ref document: 20010920 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2161281 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20010913 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20020102 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20020107 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20020111 Year of fee payment: 8 Ref country code: AT Payment date: 20020111 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20020115 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20020123 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20020124 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20020129 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20020131 Year of fee payment: 8 Ref country code: MC Payment date: 20020131 Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20010402028 Country of ref document: GR |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20020320 Year of fee payment: 8 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030104 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030105 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030131 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030131 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030131 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030131 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030804 |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20030801 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080104 |
|
PGRI | Patent reinstated in contracting state [announced from national office to epo] |
Ref country code: IT Effective date: 20110616 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20140204 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20140131 Year of fee payment: 20 Ref country code: IT Payment date: 20140131 Year of fee payment: 20 Ref country code: FR Payment date: 20140131 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20140131 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69522203 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69522203 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20150103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20150103 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20150826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20150105 |